← All organizations
Highest phase reached
Phase 3
First clinical trial
Jul 1, 2010First marketed drug
Sep 24, 2018First NDA
Sep 24, 2018Last known activity
Nov 30, 2025
Timeline
Drugs by trial phase (37 distinct, 67 trials)
Phase 3 (11 own, 0 via acquisition)
Phase 2 (20 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Arthritis
- Arthritis, Rheumatoid
- Asthma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Squamous Cell
- Coronavirus Infections
- Head and Neck Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Diseases
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Melanoma
- Mesothelioma
- Neoplasm Metastasis
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Pneumonia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Neoplasms
- Severe Acute Respiratory Syndrome
- Squamous Cell Carcinoma of Head and Neck
- Syndrome
Marketed drugs (3)
Recent trials (50)
- NCT07126158CollaboratorPhase 2Nov 30, 2025
- NCT07020221Lead sponsorPhase 1/Phase 2Jun 24, 2025
- NCT06630260CollaboratorPhase 1/Phase 2Nov 4, 2024
- NCT06682572Lead sponsorPhase 2Oct 30, 2024
- NCT06487221CollaboratorPhase 2Oct 28, 2024
- NCT06394804CollaboratorPhase 2Apr 29, 2024
- NCT06194929CollaboratorPhase 1/Phase 2Feb 8, 2024
- NCT06072781Lead sponsorPhase 3Dec 31, 2023
- NCT06072781Study directorPhase 3Dec 31, 2023
- NCT06007924CollaboratorPhase 2Aug 16, 2023
- NCT05798507CollaboratorEarly Phase 1Jul 28, 2023
- NCT05608252CollaboratorPhase 1/Phase 2Mar 31, 2023
- NCT05787561CollaboratorPhase 2Mar 15, 2023
- NCT05669482Lead sponsorPhase 1/Phase 2Jan 15, 2023
- NCT05669482Study directorPhase 1/Phase 2Jan 15, 2023
Details
- Founded
- Needham, MA, US Jul 1, 2010
- First NDA
- Sep 24, 2018
- Last known activity
- Nov 30, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval